**BACKGROUND**

- **COM701** is a novel first-in-class humanized IgG4 monoclonal antibody that binds with high affinity to poliovirus receptor related immunoglobulin domain containing (PVRIG) blocking its interaction with its ligand, PVRL2 [1].
- **PVRL2** inhibitory axis play an important role in this axis by modulating DNAM activation [2].
- **PVRIG inhibition** required for tumor growth inhibition in TIGIT KO mice [2].

**EXPLORATORY OUTCOME MEASURES**

- To evaluate preliminary antitumor activity of COM701 as monotherapy
- To assess any association of DNAM axis members with clinical outcome
- To explore evidence of COM701-mediated PD effect in blood as monotherapy as well as in combination with nivolumab.

**KEY INCLUSION CRITERIA**

- Age ≥18 yrs
- Histologically or cytologically confirmed, locally advanced or metastatic solid malignancy and has exhausted all the available standard therapy or is not a candidate for the available standard therapy
- ECOG performance status 0-1
- Prior anti-PD-1, anti-PD-L1, anti-CTLA-4, OX-40, CD137 permissible
- Adequate hematologic, hepatic and renal function

**KEY EXCLUSION CRITERIA**

- Active autoimmune disease requiring systemic therapy in the last 2 years prior to the first dose of COM701
- Symptomatic interstitial lung disease or inflammatory pneumonitis
- Untreated or symptomatic central nervous system metastases
- History of immune-related events that lead to immunotherapy treatment discontinuation

**ACCRUAL INFORMATION**

- No dose-limiting toxicities have been observed in the 7th COM701 monotherapy dose level and earlier dose levels (red box)
- No dose-limiting toxicities have been observed in the 3rd COM701 + nivolumab dose level and earlier dose levels (green box)
- As of the date of this presentation the 8th COM701 mono dose and 4th COM701 + nivolumab dose levels are open to enrollment at IV Q4 weeks schedule

**ACKNOWLEDGMENT**

- We thank the patients for participating in this clinical trial and their families
- The investigators and clinical trial sites
- Study NCT03667716 is in collaboration with Bristol-Myers Squibb

**REFERENCE**

1. Spencer L, Dier L et al, Discovery of COM701, a therapeutic antibody targeting the novel immune checkpoint PVRIG, for the treatment of cancer. I Clin Oncol; 2017; [suppl; abstr 3074]